Madison International Realty has bought a minority stake in Kadans Science Partner through investment in AXA IM Alts’ European Life Sciences platform.
Kadans Science Partner was acquired by AXA IM Alts in December 2020.
Madison believes the investment will allow Kadans to further progress its strategy for growth in Europe by undertaking new acquisition opportunities and continuing to build out its existing development opportunities.
Madison said the investment is its first in the European life sciences sector and follows a $200m commitment made to IQHQ, a US life sciences real estate owner, operator and developer, during 2020.
Kadans is a fully integrated developer, owner and operator of European science parks and lab offices with a defined focus and scale. Its portfolio currently comprises c. 167,000 sqm of operating space across 22 assets in key research locations in the Netherlands, UK and Germany, as well as eight developments which are estimated to deliver c.120,000 sqm of new space by 2024.
“Through this investment we have secured a stake in a developer and operator of life sciences real estate in Europe. Life sciences is a sector which we are already active in in the US but is still relatively new in Europe, and could be poised for further growth. The transaction is in line with our broader strategy of both investing where we have strong conviction and of taking stakes with what we believe are best in class operators, properties and businesses and working alongside highly regarded managers in sectors that we believe have the potential to grow significantly,” said Alex Lukesch, Managing Director at Madison International Realty.
